Apollomics Inc. (Class A) (APLM) carries a Roarable Rating of D+ (Sell) with 55/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-03, Apollomics Inc. (Class A) (NASDAQ: APLM) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $20.84 (0.00% 1D, market cap $60.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, APLM ranks #208 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), APLM carries a Roarable D+ (55/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SPRO (Spero Therapeutics Inc.) holds a D- grade (40/100 RQD, P/E 7.5x, ROIC 26.6%, cap $60.6M) and INCR (Intercure Ltd.) posts a D grade (46/100 RQD, P/E N/A, ROIC —, cap $60.8M). Among the 5-stock peer group, SPRO leads on earnings multiple (7.5x) while SPRO leads on capital efficiency (26.6% ROIC).
For Apollomics Inc. (Class A) (APLM), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #208 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
FRED Regime × Technicals: 56% of 52W Range • RSI-14 at 43.9 (NEUTRAL RANGE)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9
Put hedging (50% put share) caps near-term gamma upside (-13 pts vs max)
Even with a 55/100 (D+) score, APLM faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Company executives have done more routine share selling than personal cash buying lately.
Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($23.19) or 200D SMA ($18.95) invalidates the momentum regime and cuts Target Base ($20.56) toward Bear Floor ($16.04).
Apollomics Inc. (Class A) (APLM) slipped 0.00% to $20.84, trading at 56% of its 52-week range ($11.3 – $28.29). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.
Benzinga report covering Apollomics Inc. (Class A) (APLM) market action, institutional positioning, and fundamental catalysts.
Investing.com Canada report covering Apollomics Inc. (Class A) (APLM) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Apollomics Inc. (Class A) (APLM) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering Apollomics Inc. (Class A) (APLM) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering Apollomics Inc. (Class A) (APLM) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Apollomics Inc. (Class A) (APLM) market action, institutional positioning, and fundamental catalysts.
Traders Union report covering Apollomics Inc. (Class A) (APLM) market action, institutional positioning, and fundamental catalysts.
Gainers Alaunos Therapeutics (NASDAQ:TCRT) stock moved upwards by 203.8% to $3.19 during Tuesday's regular session. The company's market cap stands at $2.6 million. Picard Medical (AMEX:PMI) stock moved
Gainers Mobile-health Network (NASDAQ:MNDR) stock rose 370.0% to $4.0 during Monday's regular session. The market value of their outstanding shares is at $1.0 million. XORTX Therapeutics (NASDAQ:XRTX) shares moved
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on APLM today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for APLM. Explore sector supply chains on /butterfly.
Across 1015 tracked Health Care securities in the Roarable RQD universe, Apollomics Inc. (Class A) (APLM) ranks #208 by composite RQD confidence (55/100, grade D+) and #715 by equity capitalization ($60.4M). Within this direct 5-issuer industry benchmark cohort, SPRO leads on earnings valuation at 7.5x trailing P/E, while SPRO leads on capital efficiency and profitability with 26.6% ROIC and — gross margin. APLM currently leads its immediate peer cohort in composite quantitative strength at 55/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| APLM
ACTIVE
Apollomics Inc. (Class A) | D+ | 55/100 | — | — | — | 0.00% | $60.4M | Benchmark Subject |
| SPRO Spero Therapeutics Inc. | D- | 40/100 | 7.5x | — | 26.6% | 0.00% | $60.6M | /spro-vs-aplm → |
| INCR Intercure Ltd. | D | 46/100 | — | — | — | -0.74% | $60.8M | /incr-vs-aplm → |
| OSTX OS Therapies Incorporated | E | 30/100 | — | — | -35.0% | +0.87% | $59.8M | /ostx-vs-aplm → |
| XBIT XBiotech Inc. | E | 32/100 | — | — | -35.0% | +3.65% | $58.5M | /xbit-vs-aplm → |
Apollomics Inc. (Class A) (APLM) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $60.4M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.
As of 2026-11-03, Apollomics Inc. (Class A) (NASDAQ: APLM) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 55/100 at a spot price of $20.84 (0.00% 1D, market cap $60.4M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 7/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 14/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, APLM ranks #208 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), APLM carries a Roarable D+ (55/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, SPRO (Spero Therapeutics Inc.) holds a D- grade (40/100 RQD, P/E 7.5x, ROIC 26.6%, cap $60.6M) and INCR (Intercure Ltd.) posts a D grade (46/100 RQD, P/E N/A, ROIC —, cap $60.8M). Among the 5-stock peer group, SPRO leads on earnings multiple (7.5x) while SPRO leads on capital efficiency (26.6% ROIC).
For Apollomics Inc. (Class A) (APLM), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #208 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.
APLM last traded at $20.84 (0.00% on volume of 1,852 shares), positioning the stock -10.13% below its 50-day simple moving average ($23.19) and +9.97% above its 200-day simple moving average ($18.95). Across its 52-week range of $11.30 to $28.29, APLM sits at the 56.2% percentile with a 14-day RSI of 43.9 (NEUTRAL RANGE) and an implied next-earnings move of ±10.1% ($18.74 to $22.94).
Apollomics Inc. (Class A) (APLM) earns a live Roarable RQD composite score of 55/100, corresponding to a D+ letter grade (Roarable Sell) at a spot price of $20.84 (0.00% 1D, market capitalization $60.4M).
Apollomics Inc. (Class A) is a NASDAQ-listed issuer...1B. — describes its products, customers, or revenue model.
— for upstream dependencies, downstream customers, or sector correlation coefficients. Investors should note that the only sector context provided is the Health Care classification.
Real-time company headlines, analyst actions, and sector developments for Apollomics Inc. (Class A) (APLM) • Click "Debate This Headline" to argue it in the Roar Pit below
Benzinga report covering Apollomics Inc. (Class A) (APLM) market action, institutional positioning, and fundamental catalysts.
Investing.com Canada report covering Apollomics Inc. (Class A) (APLM) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Apollomics Inc. (Class A) (APLM) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering Apollomics Inc. (Class A) (APLM) market action, institutional positioning, and fundamental catalysts.
Stock Traders Daily report covering Apollomics Inc. (Class A) (APLM) market action, institutional positioning, and fundamental catalysts.
https://www.siam.in/ report covering Apollomics Inc. (Class A) (APLM) market action, institutional positioning, and fundamental catalysts.
Traders Union report covering Apollomics Inc. (Class A) (APLM) market action, institutional positioning, and fundamental catalysts.
Gainers Alaunos Therapeutics (NASDAQ:TCRT) stock moved upwards by 203.8% to $3.19 during Tuesday's regular session. The company's market cap stands at $2.6 million. Picard Medical (AMEX:PMI) stock moved
Forensic Balance Sheet pillar scores 13 of 20 with Altman Z 2.5 and Piotroski F 6/9, the stronger side of the RQD profile.. When you look under the hood at APLM, Fundamental Cash Engine is 12/20 with 0.0% gross margins and 0.0% ROIC. Bears are staring in the rearview mirror while institutional 13F flow (7/20) has been quietly accumulating below $28.29. My 12M target is $23.79.
Both sides have a point here — APLM's 13/20 balance sheet score keeps downside contained, so the real swing factor next earnings call is backlog and FCF conversion.
Careful chasing APLM at $20.69. Fundamental Cash Engine pillar scores 12 of 20 with ROIC 0% and FCF yield 0%, with no reported financials to offset it.. Gross margin is 0.0%, but operating margin is 0.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $17.79 on multiple compression.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Gideon Ashmere, Ellis Vennor, Tessa Rookmere, Soren Halewick, Iona Brackenford, Nadia Vellacrest, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your first name and email address below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).
Your $100,000 Virtual Cash Trading Account is active! Add your mobile number below if you want our #1 Weekly Quant Top Pick plus urgent breaking market alerts & SEC Form 4 CEO cluster-buy flashes sent straight to your phone: